Sort   by:  
 Page size 
GenomicsEGR1-mediated ibrutinib resistance
EGR1-mediated ibrutinib resistance
PRJNA925145 | ENA
ProteomicsThe conformational state of PLCγ cSH2-linker contributes to Ibrutinib resistance
Mutations in PLCγ, a substrate of the tyrosine kinase BTK, are often found in patients who develop resistance to the BTK inhibitor Ibrutinib. However, the mechanisms by which these PLCγ mutations cause Ibrutinib resistance are unclear. Under normal signaling conditions, BTK mediated phosphorylation ...
ORGANISM(S): Rattus norvegicus (Rat) 
2022-01-19 | PXD028923 | Pride
Plcγ  phospholipase c gamma  ibrutinib resistance  allostery  hdx-ms  hydrogen/deuterium exchange mass spectrometry  nmr  sh2 domain. 
ProteomicsABPP of Ibrutinib Resistance in B Cell Malignancies
Ibrutinib,a novel Bruton'styrosine kinase inhibitor, demonstrated high response rates in B-cell lymphomas but a growing number of ibrutinib treated patients relapse with resistance, fulminant progression and accelerated mortality. Using chemical proteomics and a high-throughput ex vivo assay in a re...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005734 | Pride
Ibrutinib Activity-based protein profiling B-cell cancers Lc-ms/ms 
Genomicsibrutinib resistance mantle cell lymphoma [Pt_RNA]
ibrutinib resistance mantle cell lymphoma [Pt_RNA]
PRJNA593340 | ENA
Genomicsibrutinib resistance mantle cell lymphoma [ChIP-seq]
ibrutinib resistance mantle cell lymphoma [ChIP-seq]
PRJNA593341 | ENA
Genomicsibrutinib resistance mantle cell lymphoma [RNA-seq]
ibrutinib resistance mantle cell lymphoma [RNA-seq]
PRJNA593342 | ENA
TranscriptomicsTargeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improve...
ORGANISM(S): Homo sapiens 
2026-03-10 | E-MTAB-16241 | biostudies-arrayexpress
GenomicsTargeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
PRJEB104166 | ENA
GenomicsIbrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells
Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells
PRJNA608923 | ENA
TranscriptomicsEGR1-mediated ibrutinib resistance
We established two representative ABC DLBCL cell lines (TMD8 and OCI-Ly10) with ibrutinib resistance by gradually increasing the concentration of ibrutinib during passage in culture. RNA-seq analysis demonstrated that the BCR pathway gene signature is enriched in resistant cell lines when compared t...
ORGANISM(S): Homo sapiens 
2023-12-06 | GSE223150 | GEO
Sort   by:  
 Page size